Scroll to top

News

CLINUVEL
Posted by CLINUVEL
March 31, 2021

Chair's Letter I

Direction and horizon In the last weeks, I have had investor questions...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

Media Release - CLINUVEL Expands DNA Repair Program

SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)

CLINUVEL today announced that it has reached agreement with clinical and academic...

Read More
CLINUVEL
Posted by CLINUVEL
March 10, 2021

Investor Presentation - Daiwa Investment Conference Tokyo 2021

10 March 2021 – Melbourne, Australia On 10 March 2021 CLINUVEL presented...

Read More
CLINUVEL
Posted by CLINUVEL
March 5, 2021

Appendix 3Y Change of Director's Interest Notice

CLINUVEL PHARMACEUTICALS LTD today released the attached Appendix 3Y which relates to...

Read More
We use cookies to give you the best experience.